Women Healthcare Market 2022 Size, Analysis of Issues with Geographical Overview till 2028

The women healthcare market was valued at US$ 30.5 billion in 2021 and is likely to reach US$ 42.8 billion by 2028; it is expected to grow at a CAGR of 4.8% between 2022 and 2028.

Women's health directs to the branch of medicine that focuses on treating and diagnosing diseases and conditions affecting women's physical and emotional well-being. Women usually experience unique health care challenges and are more likely to be diagnosed with certain diseases than men.

Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00024010/?utm_source=OpenPR&utm_medium=10376

Chronic diseases and conditions such as heart disease, cancer, and diabetes are the leading causes of death among women. Other health concerns impacting women include maternal health issues, urinary tract infections, sexual health and osteoporosis.

MARKET DYNAMICS:

The small and big companies operating in the women healthcare market are adopting various strategies, including regional expansion and technological advancements, to increase their market share. Growing incidence of chronic health conditions among women, rising government initiatives to restrain population growth, and increasing demand for contraceptives to control unintended pregnancies are other factors propelling the market growth. Moreover, key players' growing focus on R&D for developing advanced products is a significant market driver. Long-term extreme adverse effects of oral contraceptive pills, such as stroke, blood clots, vaginal discharge, and augmented risk of breast cancer, may limit usage and lead to restrictions by regulatory agencies. Such factors may hinder the market growth during the forecast period.

IMPACT OF COVID-19 PANDEMIC:

According to the World Health Organization (WHO), as of August 2022, there were 596,873,121 confirmed cases of COVID-19 and 6,459,684 deaths. The highest number of deaths was in the Americas, followed by Europe and Southeast Asia. Due to economic uncertainty caused by COVID-19, limited transit options and travel limitations created impediments to international trade and transportation, affecting the supply chain for women's health diagnostics and temporarily lowering demand. The COVID-19 pandemic disrupted the supply chain of contraceptives, thus affecting sexual and reproductive health services. Also, due to COVID-19, several health services was forced to suspended or postponed. Thus, during the initial days, the COVID-19 pandemic had a negative impact on the women health care market.

MARKET PLAYERS:

Bayer AG
Allergan plc
Merck & Co.
Pfizer Inc.
Amgen Inc.
Agile Therapeutics Inc.
Ferring Pharmaceuticals
Mylan N.V.
Lupin Limited
Blairex Laboratories

Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00024010/?utm_source=OpenPR&utm_medium=10376

Contact us:

If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About The Insight Partners:

The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.

This release was published on openPR.